Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab in Systemic Lupus Erythematosus (SL0005)
NCT00382837Phase 3Withdrawn
- Sponsor
- UCB
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 3, open-label, single-arm trial of epratuzumab in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoint: Long term safety. Planned start Jan 2007; status: withdrawn.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00382837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382837.